Exegenesis Bio’s Gene Therapy EXG110 Earns Orphan Drug Status for Fabry Disease
Exegenesis Bio, a leading provider of epigenetics experimental and analytical services headquartered in Hangzhou, has...
Exegenesis Bio
Exegenesis Bio Gains FDA Approval for Gene Therapy EXG102-031 in Wet AMD
Hangzhou-based clinical stage gene therapy firm Exegenesis Bio has announced receiving approval from the US...
Exegenesis Bio Secures Multi-Million Dollar Series B Financing for Gene Therapy Pipeline
Exegenesis Bio Inc., a leading gene therapy company, has successfully completed a Series B financing...